Clinical Response of AIDS-associated Kaposi's Sarcoma to HAART - 10/26/05

Treatment Interruption as a Viable Option in Patients with Lowest CD4 Cell Count >250 Cells - 10/21/05

Prevalence and Incidence of Diabetes in Minority Patients on Protease Inhibitors - 10/12/05

Switching from a Protease Inhibitor (PI) to Nevirapine Is as Effective as Continuing with PI for Viral Suppression and Improves Lipodystrophy - 9/23/05

HIV Protease Inhibitors Have Anti-malarial Effects - 8/22/05

Report on the XIV International HIV Drug Resistance Workshop: Parts 1-3 - 7/06/05

Reduced Susceptibility to Protease Inhibitors (PI) in the Absence of Primary PI Resistance-Associated Mutations - 6/27/05

Boehringer Ingelheim Wins FDA Approval to Market Protease Inhibitor Tipranavir (Aptivus) for Treatment of Drug-resistant HIV - 6/24/05

Pharmacokinetic Interaction between Chemotherapy for Non-Hodgkin's Lymphoma and Protease Inhibitors in HIV Patients - 6/24/05

Susceptibility Measurements Using Resistance Test Vectors with or without Patient-Derived C-terminus of RT, RNAseH and Integrase Are Largely Concordant - 6/27/05

Saquinavir: An Overview - 6/06/05

Metabolic Benefits But No Morphological Improvements 24 Months after Replacing a Protease Inhibitor with Abacavir, Efavirenz or Nevirapine - 6/01/05

Hematologic Benefit of Switching from Regimens Combining Protease Inhibitors and Zidovudine plus Lamivudine to Once-daily Emtricitabine, Didanosine and Efavirenz - 3/28/05  

Atazanavir (Reyataz): An Overview - 3/21/05

Simplification Therapy with Once-daily Efavirenz, Emtricitabine and Didanosine in Patients Virologically Suppressed with a Protease Inhibitor-based Regimen - 3/21/05

Meta-analysis Finds Boosted-PIs (BPI) and NNRTI-containing Regimens Provide Superior Virologic Suppression Compared to Protease Inhibitor and NRTI-containing regimens, and BPI-containing regimens offer the Greatest Increase in CD4 Cells - 3/04/05

HIV Therapy Has Saved More Than 2 Million Years of Life in US - 3/02/05

Simplification Therapy with Once Daily Emtricitabine, Didanosine, and Efavirenz in HIV Positive Adults with Viral Suppression Receiving a Protease Inhibitor-based Regimen - 2/18/05

Development of Hepatotoxicity in HIV Patients Switching at Least One Protease Inhibitor - 2/16/05

Comparison of Abacavir-based to Protease Inhibitor-based HAART Regimens: Patient Satisfaction and Adherence - 1/31/05

Substituting Abacavir for Hyperlipidemia-associated PIs Improves Lipid Profiles, Maintains Virologic Suppression, and Simplifies Treatment - 1/24/05

The Pharmacokinetics of HIV Protease Inhibitor Combinations - 1/24/05

Similar Adherence Rates Favor Different Virologic Outcomes for Patients Treated with Non Nucleoside Analogues or Protease Inhibitors - 1/10/05

Hepatotoxicity Associated with Protease inhibitor-based Regimens with or without Concurrent Ritonavir - 1/05/05

Correlation Between Plasma Concentrations of Protease Inhibitors, Medication Adherence and Virological Outcome in HIV Patients - 12/01/04

HIV Protease Inhibitors Impair Muscle Repair and Remodeling - 11/29/04

Long-term Virological Effect of HAART on Cerebrospinal Fluid and Relationship with Genotypic Resistance  - 10/18/04

Predictive Factors of Virologic Success in HIV Positive Children Treated With Lopinavir/Ritonavir  - 10/04/04

Long-Term Efficacy and Safety of Switch from Protease Inhibitor to NNRTI Nevirapine in Patients with Undetectable HIV Viral Load - 09/22/04

The Impact of Initial HAART on Future Treatment Sequences in HIV Infection - 9/15/04

Fosamprenavir: New HIV Protease Inhibitor Treatment Options - 09/13/04

Review of New PI Atazanavir - 09/13/04

24 Weeks After Substitution of Nevirapine for Protease Inhibitors, Lipid Profile and Adiponectin Concentration Improve Significantly  - 08/23/04

Updates on Antiretroviral Drug Interactions - 07/28/04

Effectiveness of Antiretroviral Therapy after Protease Inhibitor Failure  - 05/21/04

Treatment Options for Dyslipidemia Associated with the Use of Protease Inhibitors in Patients with HIV Infection and AIDS - 04/25/04

Comparison of CD4 T-cell Response in Patients Using Protease Inhibitor-based or Nevirapine-based HAART - 04/05/04